Nosantine

Nosantine

SCHEMBL2111679

CCCCCC[C@H]([C@H](C)O)n1cnc2c(=O)[nH]cnc21

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADA P00813 7/20 0.65
PDE2A O00408 3/20 0.65
CYP3A4 P08684 2/20 0.65
PDE4A P27815 1/20 0.65
PDE4B Q07343 1/20 0.65
PDE4C Q08493 1/20 0.65
PDE4D Q08499 1/20 0.65
KDM4E B2RXH2 1/20 0.65
ALDH1A1 P00352 1/20 0.65
CYP1A2 P05177 1/20 0.65
ALOX15 P16050 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HSD17B10 Q99714 1/20 0.65
TSHR P16473 1/20 0.65
HIF1A Q16665 1/20 0.65
LMNA P02545 1/20 0.64
BLM P54132 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21385659 0.85 ADA (0.46) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL20681481 0.84 HPRT1 (0.49) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL22364035 0.84 HPRT1 (0.49) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL18877201 0.84 HPRT1 (0.49) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL21127784 0.82 HPRT1 (0.47) ADAPDE2ACYP3A4PDE4APDE4B
SCHEMBL7812368 0.79 HPRT1 (0.47) ALDH1A1LMNA
(+)-Ehna SCHEMBL1742728 0.79 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B
(+)-Ehna SCHEMBL1740490 0.79 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B
(+)-Ehna SCHEMBL14985129 0.79 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B
Ehna SCHEMBL1742893 0.79 ADA (1.00) ADAPDE2ACYP3A4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
EP-2717860-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI Pharma, LLC (US) 2014-04-16 EP disclosed
US-8454582-B2 Methods and devices for the treatment of ocular conditions SURMODICS, INC. (US) 2013-06-04 US disclosed
EP-0009155-B1 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITION CONTAINING THE 9-HYDROXYALKYL-PURINES AS ACTIVE INGREDIENTS Newport Pharmaceuticals International, Inc. (US) 1982-11-17 EP disclosed
US-4340726-A PURINE COMPOUNDS HAVING IMMUNOMODULATOR, ANTIVIRAL ANTITUMOR AND ENZYME INHIBITOR ALTIVITY NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) 1982-07-20 US disclosed
EP-0036077-A2 Esters of hydroxylalkyl-purines, processes for preparing them and therapeutical composition containing these esters as active ingredients Newport Pharmaceuticals International, Inc. (US) 1981-09-23 EP disclosed
US-4221910-A IMMUNOPOTENTIATORS, VIRICIDES, ANTILEUKEMIA AGENTS NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) 1980-09-09 US disclosed
US-4221909-A P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1980-09-09 US disclosed
US-4221794-A Method of imparting immunomodulating and antiviral activity NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) 1980-09-09 US disclosed
EP-0009155-A1 9-Hydroxyalkyl-purines, processes for preparing them and therapeutical composition containing the 9-hydroxyalkyl-purines as active ingredients Newport Pharmaceuticals International, Inc. (US) 1980-04-02 EP disclosed
EP-0009154-A1 Complexes of 9-hydroxyalkyl-purines, processes for preparing them and therapeutical compositions containing the complexes as active ingredients Newport Pharmaceuticals International, Inc. (US) 1980-04-02 EP disclosed